The FDA yesterday approved Eli Lilly’s weight loss pill, orforglipron. The agency is also facing renewed scrutiny over transparency gaps related to advisory committee conflicts, and its “breakthrough” label for devices is drifting toward more ambitious — but not necessarily better-validated — AI tools.
Meanwhile, Insilico Medicine is pitching AI drug discovery as a sort of asset factory rather than a means to guaranteed approval ends.
Trump may not be done with import tariffs on drugs
The Trump administration has prepared an order that would impose a 100% tariff on some imports of patented medications and their active ingredients, according to a draft obtained by STAT reporter Daniel Payne. The tariffs could be announced as soon as today, according to a person familiar with the matter, although it’s also possible timelines and plans could shift.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
